Protagonist Therapeutics received FDA approval for ICOTYDE to treat moderate-to-severe plaque psoriasis, boosting its 'Strong Buy' rating. The company is also progressing rusfertide for polycythemia vera, with an FDA Priority Review decision expected by August 2026, supported by significant milestone and royalty potential from Takeda. Additionally, Protagonist is developing PN-881, an oral IL-17 antagonist for psoriasis and inflammatory disorders, with a phase 2b study planned for early 2027. The firm’s robust cash reserve of $849.5 million and ongoing royalty streams provide strong support for continued clinical development and operations.
Shopify reported strong Q2 2026 earnings, surpassing analyst expectations thanks to significant growth in AI-driven commerce. AI-driven traffic and orders to Shopify stores tripled year-over-year, boosting confidence in the company's AI innovation. S...
Freightos Limited reported Q2 results surpassing expectations with an EPS of -$0.03 versus -$0.05 expected and record revenue of $7.7 million, driven by a 19% increase in core platform revenue. The company narrowed its adjusted EBITDA loss to $2 mill...
Evercore ISI raised Ross Stores' price target to $276, suggesting a 12.5% upside from its current $245.36 price. The boost reflects strong expectations for Q2, with projected revenues of $6.10 billion (up 10.7%) and earnings per share of $1.92 (up 23...
SpaceX achieved a new launch cadence record with two Falcon 9 launches in 38 minutes and reported $7.814 billion in Q2 2026 revenue, beating estimates by 14.59% and growing 92% year-over-year. Key growth drivers include Starlink connectivity, AI segm...
Amazon is purchasing rare books, cutting off their spines, and scanning them at a Las Vegas facility to train its AI models. This method provides unique training data from texts that are out of print or not available online, which helps improve AI qu...
